Upcoming AWS Coverage on ZELTIQ Aesthetics Post-Earnings Results
LONDON, UK / ACCESSWIRE / December 16, 2016 / Active Wall St. blog coverage looks at the headline from St. Jude Medical, Inc. (NYSE: STJ) as the Company announced on December 15th, 2016, that it received FDA clearance for its EnSite Precision cardiac mapping system and also Advisor FL Circular Mapping Catheter, Sensor Enabled. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
One of St. Jude Medical's competitors within the Medical Appliances & Equipment space, ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), reported on November 09, 2016, its financial results for the third quarter 2016. AWS will be initiating a research report on ZELTIQ Aesthetics in the coming days.
Today, AWS is promoting its blog coverage on STJ; touching on ZLTQ. Get all of our free blog coverage and more by clicking on the links below:
St. Jude Medical stated that the new EnSite Precision cardiac mapping system is the latest addition to the company's electrophysiology portfolio. The EnSite Precision cardiac mapping system is based on the St. Jude Medical™ EnSite Velocity™ cardiac mapping system, which is utilized in more than 2,000 electrophysiology labs around the world. The EnSite AutoMap Module includes the new TurboMap feature, which will allow physicians to build a map of the heart 10 times faster than current systems using recorded data. St. Jude Medical expects this technology to be a new standard for patients experiencing arrhythmias from multiple origins in the heart.
St. Jude Medical noted that when physicians use catheter ablation to treat abnormal heart rhythm, a small area of heart tissue under the tip of the ablation catheter is heated by high-frequency energy, creating a lesion or tiny scar. As a result, this tissue is no longer capable of conducting or sustaining the arrhythmia. Cardiac mapping provides a live view of the heart so physicians can visualize and navigate cardiac anatomy to deliver more precise ablation therapy. The new EnSite Precision cardiac mapping system offers a new dual-technology platform that provides highly detailed anatomical models and maps to enable more efficient treatment of a wide range of arrhythmias — including complex arrhythmias, such as atrial fibrillation or ventricular tachycardia.
"Our new EnSite Precision cardiac mapping system was designed to give the physician a means to precisely navigate within the heart, provide higher density diagnostic data to better inform their diagnosis and allow them to use the tools that make sense for each individual patient and situation," said Dr. Srijoy Mahapatra, Vice President of clinical, medical and scientific affairs for St. Jude Medical, "The system's intelligent automation tools enable faster, more accurate high-density maps with greater consistency across cases, which are important factors in addressing the needs of today's EP labs."
In a separate press release on December 10, 2016, St. Jude Medical announced that its Board of Directors declared a Q4 2016 dividend of $0.31 per common stock. This dividend amount is equal to the dividend paid during Q1, Q2, and Q3 of 2016 and brings the total dividend declared for the year to $1.24 per share. According to the Company, the dividend is payable on January 31, 2017, to shareholders of record at the close of business on January 13, 2017, provided that the Company's pending merger with Abbott Laboratories is not effective before the close of business on the record date.
St. Jude Medical's stock is trading marginally up by 0.15%, closing Thursday's session at $79.88 on volume of 2.49 million shares, which was above the 3 months average volume of 2.36 million shares. The company's shares soared 31.10% since the beginning of the year. Additionally, the stock has rallied 30.83% in the last twelve months. The company's shares are trading at a PE ratio of 34.99 and have a dividend yield of 1.55%.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active Wall Street